|
|
| |
| Articles
by
Michael C. Irizarry |
Total Records (
2 ) for
Michael C. Irizarry |
|
 |
| |
|
| |
Roberto Gomeni
,
Monica Simeoni
,
Marina Zvartau- Hind
,
Michael C. Irizarry
,
Daren Austin
and
Michael Gold
|
| |
A novel mechanistic model based on a disease system analysis paradigm was developed to explore the role of homeostatic mechanisms involved in Alzheimer‘s disease (AD) progression. We used longitudinal AD Assessment Scale-cognitive subscale (ADAS-cog) scores from 926 subjects with AD on stable acetylcholinesterase inhibitor therapy randomized to placebo treatment in two 54-week clinical trials. Alternative mechanistic models were evaluated by assuming that the rate of change of ADAS-cog over time was jointly regulated by a process characterizing the deterioration of ADAS-cog and by a process associated with a compensatory regulatory response. The model based on a time-varying deterioration rate of ADAS-cog performed better than the model based on a time-varying homeostatic control. The covariate analysis indicated that baseline Mini-Mental State Examination score, education, age, and apolipoprotein ɛ4 genotype had a significant effect on the level and shape of the trajectories of the mean model predicted ADAS-cog change from baseline. |
|
| |
|
| |
Kristine Yaffe
,
Michael Tocco
,
Ronald C. Petersen
,
Catherine Sigler
,
Leah C. Burns
,
Christel Cornelius
,
Ara S. Khachaturian
,
Michael C. Irizarry
and
Maria C. Carrillo
|
| |
Epidemiological studies increasingly inform Alzheimer‘s disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer‘s Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct. |
|
|
|
|
| |
|
